Recently, the Journal of the American Medical Association published a multi-center clinical research paper of Ruijin Hospital, Shanghai Jiaotong University School of Medicine. This study confirms for the first time that dual antiplatelet therapy with ticagrelor combined with aspirin can significantly improve the patency rate of major saphenous vein grafts after coronary artery bypass grafting for 1 year compared with aspirin alone, and has a major reduction in heart rate. Potential trends in vascular adverse events.
Coronary artery bypass grafting is the main method for the treatment of severe coronary heart disease. The patency of bridge vessels is related to the postoperative quality of life and long-term survival of patients. Antiplatelet therapy is the cornerstone of drug treatment for the protection of bridge patency. The multi-center clinical study "DACAB" led by Prof. Qiang Zhao, Director of the Department of Cardiology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, gathers six state-of-the-art heart surgery centers and has undergone nearly four years of scientific design, strict implementation, and high-quality follow-up. Independent statistical analysis compared ticagrelor with aspirin, ticagrelor alone, and aspirin alone. The venous patency rate of venous grafts after coronary artery bypass grafting was 1 year. The results showed that, compared with the previous use of aspirin alone, double-antibiotic therapy for one year after bypass will reduce the risk of venous vascular disease by 30% to 40%.
Zhao Qiang said that for patients, the results of this study can greatly improve the long-term survival and quality of life, reduce the probability of death, myocardial infarction, relieve angina symptoms. In the expert consensus of secondary prevention (ie, drug treatment) after China's bypass surgery in 2016, double-resistance 1 year therapy after bypass surgery has been recommended. This study provides solid data support for consensus.
It is reported that once the results of the study were released on the occasion of the heavyweight clinical research session of the annual meeting of the American Heart Association in November 2017, they attracted great interest from domestic and foreign experts and scholars, and attracted attention and submissions from the Journal of the American Medical Association. The "American Medical Association Magazine" comment specifically mentioned that Zhao Qiang's generation of experts practice the technology of bridging bridges in China. The application rate exceeds that of American doctors (75% in China and 30% to 40% in the United States). Moreover, in China, secondary prevention after the bypass is highly normative, which reflects that Chinese experts are not only good at technology, but also people-oriented, and attach importance to lifelong management and treatment of patients' diseases. (Specialist reporter Zhu Fan)
Enteric Coating Vegetable Empty Capsule
Enteric Coating Vegetable Empty Capsule,Enteric Coating Vegetable Empty Capsule Size 3,Enteric Coating Vegetable Empty Capsule Size 1,Enteric Coating Vegetable Empty Capsule Size 2
Ningbo Jiangnan Capsule Co., Ltd. , https://www.ningbocapsule.com